ArticleAAPS PharmSciTech2025
Dual Drug Loaded Topical Cubosomal Gel Against Candida Albicans: An In Vitro and In Vivo Proof of Concept.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual drug approaches are gaining research interest owing to the reduction of drug resistance and additive or synergistic effects in treating fungal infections caused by Candida albicans. The present study includes the combination of ketoconazole (KTC) and eugenol (EGN) co-embedded cubosomes (KTC-EGN-CBs) for the effective treatment of candidiasis.The bio-membrane-typical framework of the cubic phase in CBs can help retain both drugs leading to enhancement of antifungal activity. KTC-EGN-CBs were developed by high-speed homogenization, followed by the probe sonication. The optimized KTC-EGN-CBs depicted lower particle size (138.8 ± 1.03 nm) and PdI (0.260 ± 0.006) with a high entrapment efficiency of KTC (79.73 ± 1.21%) and EGN (90.92 ± 2.53%). Further, KTC-EGN-CBs were loaded into the hydrogel system for ease of topical application. The ex vivo diffusion study depicted the CBs helping the KTC and EGN to exhibit significantly higher permeation and retention owing to the resemblance in cubic structure with the skin. Additionally, the in vitro antifungal study of KTC-EGN-CBs resulted in a higher zone of inhibition when compared to the plain drugs against Candida albicans. Furthermore, the effectiveness of cubosomal formulation was observed in the inhibition of planktonic growth, yeast to hyphal formation, biofilm formation, and ROS production. The antifungal activity of KTC-EGN-CBs was found to be more prominent in the infected silkworm model than the plain KTC-EGN. The cell cytotoxicity study on human keratinocyte cells and the irritation study on the hen's egg test-chorioallantoic membrane assay revealed the non-cytotoxic and non-irritant nature of the prepared cubosomes. In a nutshell, these findings demonstrated CBs as a promising carrier for KTC and EGN to effectively treat candidiasis.
Indexed as
Identifiers
40045107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.